Psychopharmacology and Psychiatry Updates

Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D.

• Learn more about our memberships here
• Earn 1.25 CME: Treatment-Resistant OCD: From SSRIs to Augmentation
• Glutamatergic Augmentation in OCD: Memantine, Riluzole, Lamotrigine and Other Agents

Faculty: Oliver Freudenreich, M.D. Host: Flavio Guzmán, M.D.

• Learn more about our memberships here
• Earn 0.75 CMEs: Quick Take Vol. 85
• Schizophrenia: Which of Seven Antipsychotics Wins on Acute Efficacy and Safety?

Faculty: Robert Hudak, M.D. Host: Flavio Guzmán, M.D.

• Learn more about our memberships here
• Earn 1.25 CME: SSRI Dosing for OCD: Beyond FDA Guidelines
• Treatment-Resistant OCD: From SSRIs to Augmentation

In this episode, we explore a new meta-analysis reconciling trazodone's real-world reputation with cautious sleep medicine guidelines, examining its effects on sleep architecture and depressive symptoms in patients with comorbid insomnia and depression, alongside its notable side effect profile. Can a decades-old antidepressant be the missing link for restorative sleep?

Faculty: Paul Zarkowski, M.D. Host: Flavio Guzmán, M.D.

• Learn more about our memberships here
• Earn 0.5 CMEs: Quick Take Vol. 85
• Trazodone for Insomnia and Comorbid Depression: Are the AASM Guidelines Relevant?

In this episode, we explore why antipsychotics cause hyperprolactinemia and sexual side effects, a leading reason patients quietly stop treatment. Dr. Oliver Freudenreich breaks down which medications carry the highest risk, the long-term health implications, and practical strategies for monitoring, switching, or augmenting therapy.

Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know
• Managing Hyperprolactinemia and Sexual Side Effects from Antipsychotic Use

In this episode, we sit down with Dr. Oliver Freudenreich to unpack EMERGENT-5, the year-long trial tracking Cobenfy's real-world durability and safety in schizophrenia. We explore whether early symptom gains hold up over time, what side effects persist, and why blood pressure monitoring now deserves a permanent spot on your checklist.

Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.5 CME: Quick Take Vol. 85
• Xanomeline-Trospium Long-Term: Does Efficacy and Safety Hold Up After One Year?

In this episode, we sit down with Dr. Oliver Freudenreich to unpack antipsychotic-induced weight gain — why it happens, which medications carry the highest risk, and how to build a proactive ABC strategy using switching, metformin, and emerging GLP-1 agonists to protect your patients' metabolic health.

Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1.25 CME: Managing Side Effects of Antipsychotics: What Every Psychiatrist Should Know
• Antipsychotic-Induced Weight Gain: Prevention and Management

In this episode, we explore whether EPA, a specific omega-3 fatty acid, can help patients with treatment-resistant depression. Dr. Derick Vergne breaks down the clinical evidence, dosing, and the anti-inflammatory mechanisms that may explain why EPA outperforms DHA in easing stubborn depressive symptoms.

Faculty: Derick E. Vergne, M.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 0.75 CMEs: Quick Take Vol. 84
• Eicosapentaenoic Acid: Effective as Adjunctive for TRD?

In this episode, we explore how liver status shapes medication choice for alcohol use disorder. Dr. Kevin Sevarino breaks down a practical algorithm for selecting between naltrexone, acamprosate, disulfiram, and other options, tailored to hepatic function, from early liver disease through decompensated cirrhosis.

Faculty: Kevin A. Sevarino, M.D.C.M., Ph.D. Host: Richard Seeber, M.D.

• Learn more about our memberships here
• Earn 1.25 CME: Pharmacotherapy of Alcohol Use Disorder
• Alcohol Use Disorder Algorithm: Medication Selection Based on Liver Status

In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done?

Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

• Learn more about our membership here
• Earn 0.75 CMEs: Quick Take Vol. 84
• GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?